By Bhanvi Satija and Maggie Fick

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump’s administration to lower drug prices last week.

Reuters spoke to seven healthcare analysts and investors. Four said Lilly could be next to make a deal, while three pointed to AstraZeneca. Others mentioned Merck, AbbVie, Regeneron and Bristol-Myers Squibb.

Reuters could not independently confirm any such deals were in the offing, but drugmakers have been jostling to get a deal after Pfizer’s September 29 agreement that pledged lower prices via Medicaid for relief on tariffs on imported medicines.

Lucy Coutts, a UK-based investment director at wealth manager JM Finn, predicted

See Full Page